NCT03578874View on ClinicalTrials.gov

SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 20, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

PO

DRUG

Capecitabine

PO

DRUG

Oxaliplatin

IV

Trial Locations (1)

Unknown

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT03578874 - SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | Biotech Hunter | Biotech Hunter